Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 5:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 2,670 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Oral placebo capsules Clear all
Completed Phase 2 Interventional Results available

A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes

NCT00650806
View directory record Official record
Conditions
Obesity
Interventions
Canagliflozin (JNJ-28431754), Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
35
States / cities
Hot Springs, Arkansas • Walnut Creek, California • Westlake Village, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 24, 2013 · Synced Oct 7, 2026, 5:10 AM EDT
Not yet recruiting Phase 2 Interventional

Nicotinamide Riboside Supplementation in Chronic Kidney Disease

NCT07693543
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Nicotinamide Riboside (NR), Matched Placebo (Capsules)
Dietary Supplement
Lead sponsor
University of California, San Diego
Other
Eligibility
30 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia

NCT00694707
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Cariprazine, Risperidone
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 60 Years
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
18
States / cities
Costa Mesa, California • Long Beach, California • Oceanside, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 7, 2026, 5:10 AM EDT
Active, not recruiting Not applicable Interventional

Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease

NCT03865992
View directory record Official record
Conditions
Breast Cancer, Joint Pain
Interventions
Curcumin, Placebo, Nanoemulsion, Quality-of-Life Assessment, Questionnaire
Dietary Supplement · Other · Behavioral
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
4
States / cities
Duarte, California • Rancho Cucamonga, California • South Pasadena, California + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment

NCT02469155
View directory record Official record
Conditions
Schizophrenia
Interventions
ITI-007, Risperidone, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
11
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Culver City, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Phase 1 Interventional

Safety Study of Chinese Herbal Therapy to Treat Asthma

NCT00601263
View directory record Official record
Conditions
Asthma
Interventions
Anti-Asthma Herbal Medical Intervention (ASHMI)
Drug
Lead sponsor
Xiu-Min Li
Other
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

BacterioPHAGE for Gastrointestinal Health 2 Study

NCT04511221
View directory record Official record
Conditions
Mild Gastrointestinal Symptoms in Healthy Adults
Interventions
Bifidobacterium animals subsp. lactis BL04+PreforPro, Bifidobacterium animals subsp. lactis BL04, Placebo
Dietary Supplement · Other
Lead sponsor
Colorado State University
Other
Eligibility
18 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

MW151-101: First-in-human Study of MW151

NCT04120233
View directory record Official record
Conditions
Drug Toxicity
Interventions
Placebo, MW151, 10mg, MW151, 20mg, MW151, 40mg, MW151, 80mg, MW151, 160mg
Drug
Lead sponsor
Linda Van Eldik
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 30, 2022 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris

NCT01320033
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CD2475/101 40 mg, Doxycycline 100 mg, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
31
States / cities
Hot Springs, Arkansas • Los Angeles, California • Denver, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Phase 3 Interventional

PrEvention of Posttraumatic Joint contractuRes With Ketotifen 2

NCT03582176
View directory record Official record
Conditions
Elbow Fracture, Elbow Injury, Elbow Dislocation
Interventions
Lactose Placebo, Ketotifen Fumarate 2mg, Ketotifen Fumarate 5mg
Drug
Lead sponsor
University of Calgary
Other
Eligibility
18 Years to 95 Years
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Baltimore, Maryland • Charlotte, North Carolina • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Isoleucine Intake and Intermediary Metabolism in Type 2 Diabetes

NCT04461236
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Oral Supplement, Placebo
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years to 84 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

NCT04618211
View directory record Official record
Conditions
Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency
Interventions
Deucrictibant, Placebo
Drug
Lead sponsor
Pharvaris Netherlands B.V.
Industry
Eligibility
18 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease

NCT00321984
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
947 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
153
States / cities
Alabaster, Alabama • Birmingham, Alabama • Hueytown, Alabama + 150 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2011 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

NCT01153009
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine, Duloxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
56
States / cities
Beverly Hills, California • Chino, California • Garden Grove, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 7, 2026, 5:10 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Postpartum Low-Dose Aspirin and Preeclampsia

NCT03667326
View directory record Official record
Conditions
Preeclampsia Postpartum
Interventions
Aspirin tablet, Placebo oral capsule
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection

NCT04781387
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
CRS3123, Active Comparator
Drug
Lead sponsor
Crestone, Inc
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
18
States / cities
Fullerton, California • Lancaster, California • Mission Hills, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 7, 2026, 5:10 AM EDT
Not listed Phase 2 Interventional

Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson Disease

NCT02812147
View directory record Official record
Conditions
Parkinson Disease
Interventions
L-DOPS, Placebo
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
30 Years to 83 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 7, 2026, 5:10 AM EDT
Terminated Phase 1Phase 2 Interventional

Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction

NCT00550849
View directory record Official record
Conditions
Liver Disease
Interventions
RTA 402
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Supplementation With 1 mg of KGA-10 Daily (a Novel Environmentally-derived Mycolicibacterium) for Stress, Sleep, and Inflammation

NCT07604038
View directory record Official record
Conditions
Stress Resilience, Systemic Inflammation, General Wellbeing, Sleep Quality, Safety
Interventions
Mycolicibacterium petrae KGA-10 (heat-killed), Placebo (microcrystalline cellulose)
Dietary Supplement
Lead sponsor
Kioga Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 7, 2026, 5:10 AM EDT
Recruiting Phase 3 Interventional

Study of Tadalafil vs. Placebo for Improving Hemodynamics and End-Organ Dysfunction in Fontan Physiology

NCT05206955
View directory record Official record
Conditions
Fontan Palliation
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 7, 2026, 5:10 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

The Use of Low Dose Metronidazole to Decrease Postoperative Pain After Endometriosis Surgery

NCT04554693
View directory record Official record
Conditions
Endometriosis, Endometriosis-related Pain
Interventions
Metronidazole Oral, Placebo
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate

NCT02706873
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo to Upadacitinib, Methotrexate, Placebo to Methotrexate, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
32
States / cities
La Mesa, California • Palm Desert, California • Daytona Beach, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo

NCT01426269
View directory record Official record
Conditions
Rosacea
Interventions
Doxycycline, Metronidazole, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 80 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
Santa Monica, California • Coral Gables, Florida • Corbin, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 7, 2026, 5:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of a Hypolipidemic Agent in Healthy Normal Volunteers

NCT00685737
View directory record Official record
Conditions
Hyperlipidemia
Interventions
1-MNA, Placebo
Drug
Lead sponsor
Pharmena North America
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 27, 2008 · Synced Oct 7, 2026, 5:10 AM EDT